2,266 Shares in Natera, Inc. $NTRA Acquired by Chicago Capital LLC

Chicago Capital LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,266 shares of the medical research company’s stock, valued at approximately $365,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of NTRA. Guided Capital Wealth Management LLC boosted its stake in shares of Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after buying an additional 66 shares during the last quarter. Main Management ETF Advisors LLC lifted its holdings in Natera by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock valued at $743,000 after acquiring an additional 72 shares during the period. Yousif Capital Management LLC boosted its position in Natera by 4.5% in the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock worth $271,000 after purchasing an additional 72 shares during the last quarter. Wedmont Private Capital grew its stake in shares of Natera by 4.9% during the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock valued at $256,000 after purchasing an additional 74 shares during the period. Finally, Blue Trust Inc. grew its stake in shares of Natera by 23.1% during the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 81 shares during the period. 99.90% of the stock is owned by institutional investors.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 3,848 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $229.08, for a total value of $881,499.84. Following the completion of the sale, the chief executive officer owned 136,568 shares of the company’s stock, valued at $31,284,997.44. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Herm Rosenman sold 48,419 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $227.42, for a total value of $11,011,448.98. Following the transaction, the director owned 20,342 shares of the company’s stock, valued at $4,626,177.64. This trade represents a 70.42% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 343,280 shares of company stock worth $73,566,011. 5.63% of the stock is currently owned by insiders.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Piper Sandler increased their price objective on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. BTIG Research upped their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Barclays increased their price target on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Evercore ISI upped their price objective on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Fifteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.29.

Natera Trading Up 4.8%

Shares of NASDAQ NTRA opened at $248.74 on Wednesday. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $249.15. The firm’s 50-day moving average price is $224.18 and its 200-day moving average price is $184.78. The stock has a market capitalization of $34.41 billion, a price-to-earnings ratio of -108.62 and a beta of 1.62.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.26) EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.